Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans

Ahmed Yousseif, Julian Emmanuel, Efthimia Karra, Queensta Millet, Mohamed Elkalaawy, Andrew D Jenkinson, Majid Hashemi, Marco Adamo, Nicholas Finer, Alberic G Fiennes, Dominic J Withers, Rachel L Batterham, Ahmed Yousseif, Julian Emmanuel, Efthimia Karra, Queensta Millet, Mohamed Elkalaawy, Andrew D Jenkinson, Majid Hashemi, Marco Adamo, Nicholas Finer, Alberic G Fiennes, Dominic J Withers, Rachel L Batterham

Abstract

Laparoscopic Roux-en-Y gastric bypass (LRYGBP) reduces appetite and induces significant and sustainable weight loss. Circulating gut hormones changes engendered by LRYGBP are implicated in mediating these beneficial effects. Laparoscopic sleeve gastrectomy (LSG) is advocated as an alternative to LRYGBP, with comparable short-term weight loss and metabolic outcomes. LRYGBP and LSG are anatomically distinct procedures causing differential entero-endocrine cell nutrient exposure and thus potentially different gut hormone changes. Studies reporting the comparative effects of LRYGBP and LSG on appetite and circulating gut hormones are controversial, with no data to date on the effects of LSG on circulating peptide YY3-36 (PYY3-36) levels, the specific PYY anorectic isoform. In this study, we prospectively investigated appetite and gut hormone changes in response to LRYGBP and LSG in adiposity-matched non-diabetic patients. Anthropometric indices, leptin, fasted and nutrient-stimulated acyl-ghrelin, active glucagon-like peptide-1 (GLP-1), PYY3-36 levels and appetite were determined pre-operatively and at 6 and 12 weeks post-operatively in obese, non-diabetic females, with ten undergoing LRYGBP and eight adiposity-matched females undergoing LSG. LRYGBP and LSG comparably reduced adiposity. LSG decreased fasting and post-prandial plasma acyl-ghrelin compared to pre-surgery and to LRYGBP. Nutrient-stimulated PYY3-36 and active GLP-1 concentrations increased post-operatively in both groups. However, LRYGBP induced greater, more sustained PYY3-36 and active GLP-1 increments compared to LSG. LRYGBP suppressed fasting hunger compared to LSG. A similar increase in post-prandial fullness was observed post-surgery following both procedures. LRYGBP and LSG produced comparable enhanced satiety and weight loss. However, LSG and LRYGBP differentially altered gut hormone profiles.

Conflict of interest statement

All authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Fasting and nutrient-stimulated appetite, gut hormones, glucose and insulin for the LRYGBP and LSG groups pre-operatively. (A) Temporal hunger visual analogue scales (VAS) ratings for the LRYGBP (red, filled squares) and LSG (blue, filled circles). (B) Temporal fullness VAS for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. (C) Plasma acyl-ghrelin temporal profile for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. (D) Plasma PYY3-36 temporal profile for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. (E) Plasma active GLP-1 temporal profile for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. (F) Plasma glucose temporal profile for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. (G) Plasma insulin temporal profile for the LRYGBP (red, filled squares) and LSG (blue, filled circles) groups. Results are expressed as mean ± SEM
Fig. 2
Fig. 2
The effects of LRYGBP and LSG on plasma fasting, meal-stimulated acyl-ghrelin and acyl-ghrelinAUC0–180. Plasma acyl-ghrelin temporal profile in response to the test-meal for LRYGBP (a) and LSG (b) groups at pre-surgery (black, solid squares), and at 6w and 12w post-operatively (red, solid circles and green, solid triangles, respectively). c Acyl-ghrelinAUC0–180 for LRYGBP (black, solid columns) and LSG groups (grey, solid columns) at pre-surgery and at 6w and 12w post-operatively. Results are expressed as mean ± SEM. *p < 0.05, within-group at 6w post-operatively compared to pre-surgery; †p < 0.05, within-group comparisons at 12w post-operatively versus pre-surgery; ‡p < 0.05, within-group 6w versus 12w comparison. The p values at the right upper corner of c indicate one-way ANOVA within-group analysis. Within-group Bonferroni post hoc and between-group t test significance is indicated over the corresponding bars
Fig. 3
Fig. 3
The effects of LRYGBP and LSG on fasting, meal-stimulated plasma concentrations and area-under-the curve (AUC0–180) for PYY3–36 and active GLP-1. Plasma PYY3-36 temporal profile in response to the test-meal for LRYGBP (a) and LSG (b) groups at pre-surgery (black, solid squares) and at 6w and 12w post-operatively (red, solid circles and green, solid triangles, respectively). Plasma active GLP-1 temporal profile in response to the test-meal for LRYGBP (c) and LSG (d) groups at pre-surgery (black, solid squares) and at 6w and 12w post-operatively (red, solid circles and green, solid triangles, respectively). PYY3-36AUC0-180 (e) and active GLP-1AUC0-180 (f) for LRYGBP (black, solid columns) and LSG groups (grey, solid columns) at pre-surgery and at 6w and 12w post-operatively. Results are expressed as mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 within-group at 6w post-operatively compared to pre-surgery. †p < 0.05, ††p < 0.01 and †††p < 0.001 for within-group comparisons at 12w post-operatively versus pre-surgery. The p values at the right upper corner of e and f indicate one-way ANOVA within-group analysis. Within-group Bonferroni post hoc and between-group t test significance is indicated over the corresponding bars
Fig. 4
Fig. 4
The effects of LRYGBP and LSG on fasting, meal-stimulated and area-under the curve (AUC0–180) for subjective hunger and fullness VAS ratings. Hunger VAS temporal profile in response to the test-meal for LRYGBP (a) and LSG (b) groups at pre-surgery (black, solid squares), and at 6w and 12w post-operatively (red, solid circles and green, solid triangles, respectively). Fullness VAS temporal profile in response to the test-meal for LRYGBP (c) and LSG (d) groups at pre-surgery (black, solid squares) and at 6w and 12w post-operatively (red, solid circles and green, solid triangles, respectively). HungerAUC0-180 (e) and fullnessAUC0-180 (f) for LRYGBP (black, solid columns) and LSG groups (grey, solid columns) at pre-surgery and at 6w and 12w post-operatively. Results are expressed as mean ± sem. *p < 0.05, **p < 0.01 and ***p < 0.001 within-group at 6w post-operatively compared to pre-surgery. †p < 0.05, ††p < 0.01 and †††p < 0.001 for within-group comparisons at 12w post-operatively versus pre-surgery. The p values at the right upper cornere and f indicate one-way ANOVA within-group analysis. Within-group Bonferroni post hoc and between-group t test significance is indicated over the corresponding bars

References

    1. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65. doi: 10.1001/jama.2011.1914.
    1. Scott WR, Batterham RL. Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: understanding weight loss and improvements in type 2 diabetes after bariatric surgery. Am J Physiol Regul Integr Comp Physiol. 2011;301:R15–R27. doi: 10.1152/ajpregu.00038.2011.
    1. Morinigo R, Moize V, Musri M, et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735–1740. doi: 10.1210/jc.2005-0904.
    1. Laferrere B. Effect of gastric bypass surgery on the incretins. Diabetes Metab. 2009;35:513–517. doi: 10.1016/S1262-3636(09)73458-5.
    1. Olivan B, Teixeira J, Bose M, et al. Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann Surg. 2009;249:948–953. doi: 10.1097/SLA.0b013e3181a6cdb0.
    1. Gould JC, Kent KC, Wan Y, et al. Perioperative safety and volume: outcomes relationships in bariatric surgery: a study of 32,000 patients. J Am Coll Surg. 2011;213:771–777. doi: 10.1016/j.jamcollsurg.2011.09.006.
    1. Deitel M, Gagner M, Erickson AL, et al. Third international summit: current status of sleeve gastrectomy. Surg Obes Relat Dis. 2011;7:749–759. doi: 10.1016/j.soard.2011.07.017.
    1. Chambers AP, Jessen L, Ryan KK, et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology. 2011;141:950–958. doi: 10.1053/j.gastro.2011.05.050.
    1. Paluszkiewicz R, Kalinowski P, Wroblewski T, et al. Prospective randomized clinical trial of laparoscopic sleeve gastrectomy versus open Roux-en-Y gastric bypass for the management of patients with morbid obesity. Wideochir Inne Tech Malo Inwazyjne. 2012;7:225–232.
    1. Vidal P, Ramon JM, Goday A, et al. Laparoscopic gastric bypass versus laparoscopic sleeve gastrectomy as a definitive surgical procedure for morbid obesity. Mid-term results, Obes Surg. 2013;23:292–299. doi: 10.1007/s11695-012-0828-4.
    1. Hillman JB, Tong J, Tschop M. Ghrelin biology and its role in weight-related disorders. Discov Med. 2011;11:521–528.
    1. Hosoda H, Doi K, Nagaya N, et al. Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem. 2004;50:1077–1080. doi: 10.1373/clinchem.2003.025841.
    1. Chandarana K, Drew ME, Emmanuel J, et al. Subject standardization, acclimatization, and sample processing affect gut hormone levels and appetite in humans. Gastroenterology. 2009;136:2115–2126. doi: 10.1053/j.gastro.2009.02.047.
    1. Batterham RL, Heffron H, Kapoor S, et al. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab. 2006;4:223–233. doi: 10.1016/j.cmet.2006.08.001.
    1. Batterham RL, Bloom SR. The gut hormone peptide YY regulates appetite. Ann N Y Acad Sci. 2003;994:162–168. doi: 10.1111/j.1749-6632.2003.tb03176.x.
    1. Nadkarni PP, Costanzo RM, Sakagami M. Pulmonary delivery of peptide YY for food intake suppression and reduced body weight gain in rats. Diabetes Obes Metab. 2011;13:408–417. doi: 10.1111/j.1463-1326.2011.01363.x.
    1. Chelikani PK, Haver AC, Reidelberger RD. Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology. 2005;146:879–888. doi: 10.1210/en.2004-1138.
    1. Sloth B, Holst JJ, Flint A, et al. Effects of PYY1-36 and PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab. 2007;292:E1062–E1068. doi: 10.1152/ajpendo.00450.2006.
    1. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. doi: 10.1056/NEJMoa1105816.
    1. Valderas JP, Irribarra V, Rubio L, et al. Effects of sleeve gastrectomy and medical treatment for obesity on glucagon-like peptide 1 levels and glucose homeostasis in non-diabetic subjects. Obes Surg. 2011;21:902–909. doi: 10.1007/s11695-011-0375-4.
    1. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234–241. doi: 10.1097/SLA.0b013e3181ae32e3.
    1. Morinigo R, Vidal J, Lacy AM, et al. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 2008;247:270–275. doi: 10.1097/SLA.0b013e31815f6e77.
    1. Chronaiou A, Tsoli M, Kehagias I, et al. Lower ghrelin levels and exaggerated postprandial peptide-YY, glucagon-like peptide-1, and insulin responses, after gastric fundus resection, in patients undergoing Roux-en-Y gastric bypass: a randomized clinical trial. Obes Surg. 2012;22:1761–1770. doi: 10.1007/s11695-012-0738-5.
    1. R. Barazzoni, A. Semolic, M.R. Cattin, M. Zanetti, G. Guarnieri. Acylated ghrelin limits fat accumulation and improves redox state and inflammation markers in the liver of high-fat-fed rats. Obesity (Silver Spring). 2013.
    1. Melissas J, Daskalakis M, Koukouraki S, et al. Sleeve gastrectomy-a “food limiting” operation. Obes Surg. 2008;18:1251–1256. doi: 10.1007/s11695-008-9634-4.
    1. Baumann T, Kuesters S, Grueneberger J, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy–preliminary results. Obes Surg. 2011;21:95–101. doi: 10.1007/s11695-010-0317-6.
    1. J. Melissas, A. Leventi, I. Klinaki, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Annals of Surgery. 2012.
    1. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247:401–407. doi: 10.1097/SLA.0b013e318156f012.
    1. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and Hormonal Changes After Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: a Randomized. Obes Surg: Prospective Trial; 2012.
    1. Ramon JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16:1116–1122. doi: 10.1007/s11605-012-1855-0.
    1. F. Romero, J. Nicolau, L. Flores, R. Casamitjana, A. Ibarzabal, A. Lacy, J. Vidal, Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects, Surg Endosc, (2012)
    1. Valderas JP, Irribarra V, Boza C, et al. Medical and surgical treatments for obesity have opposite effects on peptide YY and appetite: a prospective study controlled for weight loss. J Clin Endocrinol Metab. 2010;95:1069–1075. doi: 10.1210/jc.2009-0983.
    1. Alam ML, Van der Schueren BJ, Ahren B, et al. Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:378–381. doi: 10.1111/j.1463-1326.2011.01358.x.
    1. Kirchner H, Gutierrez JA, Solenberg PJ, et al. GOAT links dietary lipids with the endocrine control of energy balance. Nat Med. 2009;15:741–745. doi: 10.1038/nm.1997.
    1. Gonzalez CR, Vazquez MJ, Lopez M, et al. Influence of chronic undernutrition and leptin on GOAT mRNA levels in rat stomach mucosa. J Mol Endocrinol. 2008;41:415–421. doi: 10.1677/JME-08-0102.
    1. Goebel-Stengel M, Hofmann T, Elbelt U, et al. The ghrelin activating enzyme ghrelin-O-acyltransferase (GOAT) is present in human plasma and expressed dependent on body mass index. Peptides. 2013;43:13–19. doi: 10.1016/j.peptides.2013.02.011.
    1. Gagner M, Deitel M, Kalberer TL, et al. The second international consensus summit for sleeve gastrectomy. Surg Obes Relat Dis. 2009;5:476–485. doi: 10.1016/j.soard.2009.06.001.
    1. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi: 10.1007/BF00280883.
    1. Sundbom M, Holdstock C, Engstrom BE, et al. Early changes in ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality? Obes Surg. 2007;17:304–310. doi: 10.1007/s11695-007-9056-8.
    1. Bohdjalian A, Langer FB, Shakeri-Leidenmuhler S, et al. Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year results for weight loss and ghrelin. Obes Surg. 2010;20:535–540. doi: 10.1007/s11695-009-0066-6.
    1. Falken Y, Hellstrom PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227–2235. doi: 10.1210/jc.2010-2876.
    1. Rigamonti AE, Agosti F, Compri E, et al. Anorexigenic postprandial responses of PYY and GLP1 to slow ice cream consumption: preservation in obese adolescents, but not in obese adults. Eur J Endocrinol. 2013;168:429–436. doi: 10.1530/EJE-12-0867.
    1. Kim BJ, Carlson OD, Jang HJ, et al. Peptide YY is secreted after oral glucose administration in a gender-specific manner. J Clin Endocrinol Metab. 2005;90:6665–6671. doi: 10.1210/jc.2005-0409.
    1. Neary MT, Batterham RL. Gut hormones: implications for the treatment of obesity. Pharmacol Ther. 2009;124:44–56. doi: 10.1016/j.pharmthera.2009.06.005.
    1. Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52. doi: 10.1007/BF02427280.
    1. Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2004;151:573–577. doi: 10.1530/eje.0.1510573.
    1. Campos GM, Rabl C, Mulligan K, et al. Factors associated with weight loss after gastric bypass. Arch Surg. 2008;143:877–883. doi: 10.1001/archsurg.143.9.877.

Source: PubMed

3
Předplatit